Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Large Cap | Pharmaceuticals & Drugs
1175.55
-10.90 (-0.92%)
< Home < Back

Dr Reddy’s Laboratories launches Ropinirole Hydrochloride XR tablets

Date: 07-06-2012

Dr Reddy’s Laboratories has launched Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg), a bioequivalent generic version of REQUIP XL tablets in the US market, following United States Food & Drug Administration (USFDA’s) approval for Dr Reddy’s ANDA for Ropinirole Hydrochloride XR (Extended Release).

The REQUIP XL brand has US sales of approximately $58 million for the most recent twelve months ending March 2012 according to the IMS Health.

Dr Reddy’s Ropinirole Hydrochloride XR (Extended Release) tablets (2mg, 4Mg, 6 mg, 8 mg and 12mg) are available in 30 and 90 count bottles sizes, 8 mg and 12 mg are available  in 30 count bottle sizes.